Last updated: May 2026. This page summarizes publicly reported information about Amino Asylum’s June 2025 FDA enforcement action and the questions former customers should ask when choosing a replacement research peptide vendor.
Background: who Amino Asylum was
Amino Asylum operated for several years as a US-facing research peptide retailer with a broad catalog covering the standard peptide families: BPC-157, TB-500, growth-hormone-secretagogues, MOTS-C, NAD+, GLP-receptor research compounds, and various nootropics. The brand built a customer base in the recreational research community, advertised through forum sponsorships, and was a frequent answer in “who do you order from?” threads on Reddit and Evolutionary.org.
Like most vendors in this space, Amino Asylum sold its products with the standard “for research use only, not for human consumption” disclaimer. The brand was generally considered mid-tier on price and high-volume on shipping cadence.
The June 2025 enforcement action
According to coverage from Muscle & Brawn (muscleandbrawn.com) and corroborating posts on PSPeptides, PeptideExaminer, and the Evolutionary.org forum, the FDA executed a warehouse-level enforcement action against Amino Asylum’s fulfillment operation on or around June 18, 2025.
The pattern that followed is the one researchers in this space have seen before: the storefront went offline within days, customer support email queues stopped being processed, social media accounts went silent, and no shipments left the warehouse after the raid date. As of this writing, the site remains offline. No legal proceedings, settlements, or restart announcements have been publicly reported.
It is worth being precise about what the public record does and does not show. The widely-reported facts are: (1) an enforcement action occurred at the warehouse, (2) the site has been offline since, (3) no successor brand has launched. Beyond that, any specific allegations about products, labeling, or distribution are matters for the FDA and any future court filings — not something this page is in a position to characterize.
Why this matters for the broader research peptide market
2025-2026 has been a consolidation period for the research peptide industry. Amino Asylum (FDA action, June 2025) and Science.bio (voluntary closure citing regulatory compliance, January 27, 2026) are two of the highest-profile exits, and they happened seven months apart. For research customers, the practical implication is twofold:
- Vendor diligence matters more than it used to. The cost of picking a vendor that exits is no longer just inconvenience — it can mean lost prepayment, lost loyalty balances, and disrupted long-running protocols.
- Domestic supply, third-party testing, and clear documentation are now table stakes. The vendors that survive this consolidation are the ones who can show the chain of custody from synthesis to shipment.
WELCOME20 — 20% off your first PCA order, $75 minimum. Shop now.
How to evaluate any replacement vendor
If you are a displaced Amino Asylum customer, here is the checklist worth running on any vendor before you place an order:
- COA per lot, not per product. A vendor that posts a single “sample COA” from 2022 is not the same as a vendor that posts a fresh COA tied to the specific lot in stock. Ask which.
- Domestic fulfillment. US-based fulfillment means no customs holds and no opaque international shipping windows. Ask where orders ship from.
- Inventory model. Vendors who hold inventory in a domestic warehouse can ship next-day. Vendors who drop-ship from overseas cannot. Ask which model the vendor uses.
- Product class discipline. The historically risky categories for research vendors involve products that look like compounded prescription drugs marketed for human use. A vendor that stays in the research-only lane on labeling, marketing, and product mix has a structurally lower regulatory exposure.
- Customer support response time. Email the vendor a pre-sales question before you order. A 24-48 hour response from a real person is a good sign. Silence is the warning sign Amino Asylum customers wish they had heeded.
- Refund and reshipment policy. Read it before you order, not after.
How Pure Chain Aminos meets this checklist
- COA per lot. Every product page links to the COA for the lot currently in stock.
- US-based fulfillment. Orders ship from a domestic facility.
- Inventory model. PCA holds inventory for top SKUs. The catalog reflects what is on the shelf.
- Research-only product mix. No compounded GLP-1 prescription mimics, no human-use marketing, no off-label medical claims.
- Live customer support. Pre-sales questions get answered.
- Clear refund policy. Linked from the footer of every page.
Top SKUs to start with
- BPC-157 10mg — $59.99
- BPC-157 15mg — $89.99
- TB-500 10mg — $79.99
- GLP3-R 20mg — $224.99
- GLP2-T 30mg — $119.99
- NAD+ 1000mg — $99.99
- Tesamorelin 10mg — $89.99
Research library
For background reading on the most-requested compounds: BPC-157 · TB-500 · GLP-3 Receptor · GLP-2-T · NAD+ · MOTS-C · Retatrutide · Bacteriostatic water reconstitution guide.
Apply WELCOME20 at checkout — 20% off any order $75+. Browse the full catalog.
See also
- Amino Asylum Shut Down: What Happened in the June 2025 FDA Raid
- Amino Asylum Coupon Codes (No Longer Active) — Use This Instead
- Pure Chain Aminos vs Amino Asylum (Closed): Vendor Comparison and Migration Guide
Frequently asked questions
What exactly was the FDA action?
Per public reporting (Muscle & Brawn, PSPeptides, PeptideExaminer, Evolutionary.org), an enforcement action was executed at the Amino Asylum warehouse on or about June 18, 2025. Beyond that, the specifics are matters for the FDA and any future court filings. This page does not characterize the underlying allegations.
Why did the site go offline so quickly?
This is the typical pattern after a warehouse-level enforcement action: inventory and shipping records become subject to the action, the fulfillment operation halts, and the storefront is taken down (often by the operator) within days. Customer-facing infrastructure usually goes silent at the same time.
Are other research peptide vendors at risk?
The two highest-profile exits in the past year were Amino Asylum (June 2025, enforcement-driven) and Science.bio (January 2026, voluntary, citing regulatory compliance). Vendors that operate within the research-only product class, hold US-based inventory, and publish per-lot COAs have a structurally lower regulatory exposure than vendors that branch into compounded prescription mimics or international drop-ship models.
How do I know PCA will still be here in a year?
The honest answer is that no vendor can prove a future. What we can show is the operational pattern: research-only catalog, US fulfillment, per-lot COA publication, in-stock inventory rather than drop-ship, live customer support, and a clean refund policy. Those are the structural indicators that correlate with longevity in this space.
What we do not claim to know
This page is built on publicly reported information. We do not have non-public information about Amino Asylum, the underlying enforcement action, or the company\’s internal operations. If you are a former customer with a specific question about your prior orders or account, the FDA and your card issuer are the right channels for that information \— not this page.
Sources cited: Muscle & Brawn — https://muscleandbrawn.com/reviews/amino-asylum-raided-in-2025/. Additional coverage: PSPeptides, PeptideExaminer, Evolutionary.org forum.
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.